Trials / Terminated
TerminatedNCT03471559
Cannabidiol - an in Vivo Innovative Drug Delivery Study
Cannabidiol as a Medication for Neuropsychiatric and Other Medical Conditions - an in Vivo Innovative Drug Delivery Study
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Central Institute of Mental Health, Mannheim · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
Basic characterization of the drug delivery system for cannabidiol. A comparative bioavailability study.
Detailed description
This study aims to investigate an innovative pharmaceutical preparation of cannabidiol. Thus, a comparative bioavailability study will be conducted, comparing cannabidiol capsules (reference formulation) with an intranasal cannabidiol gel (test formulation), with the further aim to find an appropriate dosing of the new pharmaceutical preparation. The intranasal administration may also be suitable to reduce the high variability in the bioavailability of cannabidiol observed for the current oral administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cannabidiol | single or multiple dosing |
Timeline
- Start date
- 2018-12-10
- Primary completion
- 2019-06-30
- Completion
- 2019-08-29
- First posted
- 2018-03-20
- Last updated
- 2020-07-01
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03471559. Inclusion in this directory is not an endorsement.